The United Kingdom and the United States have signed a landmark trade agreement that will guarantee zero tariffs on British pharmaceutical products going into the American market.
Agreement Details of the Accord
In exchange for the tariff guarantee, the UK has committed to boost spending on drugs through the National Health Service (NHS). This commitment secures that import taxes on these key products will be held at nothing for a period of 36 months.
This agreement is in response to earlier warnings to dramatically increase duties on branded drug imports, with figures floated reaching one hundred percent.
"This arrangement with the United Kingdom strengthens the international landscape for new treatments and introduces long-overdue balance to transatlantic medicine commerce," a statement noted.
Trade Significance
Pharmaceuticals represent one of the the United Kingdom's most significant goods shipped to the America, which is clearly the largest destination for large UK drugmakers.
Statistics show that in the year to the end of September, the UK exported drugs worth billions to the US. This figure made up a significant portion of total UK exports in that period.
"This deal protects work, stimulates capital expenditure and paves the way for the UK to establish itself as a international leader for life sciences," the Business and Trade Secretary remarked.
Specific UK Commitments
The deal involves several key pledges from the United Kingdom:
- Price Threshold Increase: The UK will lift the cost ceiling at which it deems new medicines to be prohibitively costly by twenty-five percent.
- Boosted Medicine Funding: There is a goal to increase total NHS spending on drugs from 0.3% of Gross Domestic Product to 0.6% over the following ten-year period.
- Rebate Cap: The percentage drug companies must pay back to the NHS to prevent overspending will be limited at fifteen percent. Last year, refunds were more than twenty percent.
Recent Tensions
This agreement comes amid a ongoing row between the drug companies and the UK government over spending levels and NHS adoption.
The disagreement were heightened by arguments that American patients were charged a premium for the equivalent treatments than consumers in the UK and Europe.
Over the last 18 months, several large manufacturing plans in the UK have been halted or cancelled, while substantial investments have been directed toward projects in the United States.
One official publicly accepted that the NHS must spend more on drugs, noting that its expenditure on drugs had declined as a share of its total funding over the last ten years.
